Advances in immunotherapy for head and neck squamous cell carcinoma based on the tumor immune microenvironment
10.12025/j.issn.1008-6358.2025.20250627
- VernacularTitle:基于肿瘤免疫微环境的头颈部鳞状细胞癌免疫治疗进展
- Author:
Haopu LI
1
;
Hui YAO
1
;
Guanghao ZHU
1
;
Jingjie WANG
1
;
Minhui ZHU
1
Author Information
1. Department of Otolaryngology, Head and Neck Surgery, the First Affiliated Hospital of Naval Medical University (Changhai Hospital), Shanghai 200433, China.
- Publication Type:Review
- Keywords:
immunotherapy;
head and neck squamous cell carcinoma;
tumor microenvironment;
immune checkpoint inhibitor;
immunotherapeutic strategy
- From:
Chinese Journal of Clinical Medicine
2025;32(6):1030-1042
- CountryChina
- Language:Chinese
-
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is a tumor characterized by immunosuppressive tumor microenvironment (TME) and poor prognosis. Its complex immune evasion mechanisms are primarily related to T cell dysfunction and the suppression of anti-tumor immune responses. Immunotherapy aims to modulate the patient’s immune system to recognize and eliminate tumor cells, thereby achieving therapeutic goals. Studies have demonstrated that the TME plays a pivotal role in HNSCC pathogenesis, facilitating tumorigenesis, progression, and therapy resistance, ultimately contributing to adverse clinical outcomes. Advances in technology have deepened understanding of the TME, paving the way for novel therapeutic interventions in HNSCC. This review comprehensively summarizes the efficacy and safety of TME-targeted immunotherapies, integrating evidence from published clinical trials, while proposing insights for future research to develop more effective therapeutic strategies.
